The Technical Analyst
Regencell Bioscience [RGC]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Regencell Bioscience Price, Forecast, Insider, Ratings, Fundamentals & Signals
-5.56% $5.10
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 66.37 mill |
| EPS: | -0.450 |
| P/E: | -11.33 |
| Earnings Date: | Jan 26, 2024 |
| SharesOutstanding: | 13.01 mill |
| Avg Daily Volume: | 0.0042 mill |
| RATING 2024-04-24 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -11.33 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.24x |
| Company: PE -11.33 | industry: PE 47.78 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.0846 (-98.34%) $-5.02 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 4.47 - 5.73 ( +/- 12.35%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2018-02-28 | Anschutz Philip F | Sell | 12 440 000 | CLASS A COMMON STOCK |
| 2018-02-28 | Anschutz Philip F | Sell | 23 708 639 | CLASS B COMMON STOCK |
| 2018-02-28 | Campbell Michael L | Sell | 703 660 | Class A Common Stock |
| 2018-02-28 | Yemenidjian Alex | Sell | 21 880 | Class A Common Stock |
| 2018-02-28 | Tyrrell Jack | Sell | 136 684 | Class A Common Stock |
| INSIDER POWER |
|---|
| 0.00 |
| Last 97 transactions |
| Buy: 583 544 | Sell: 71 137 085 |
Forecast:
16:00 - $5.10
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $5.10
Forecast 2: 16:00 - $5.10
Forecast 3: 16:00 - $5.10
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $5.10 (-5.56% ) |
| Volume | 0.0026 mill |
| Avg. Vol. | 0.0042 mill |
| % of Avg. Vol | 63.08 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For RGC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
RGC
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Last 10 Buy Signals
Latest Press Releases
2022-09-12 09:15:00 - Press Release
Regencell Bioscience's Standardized Formulae Are Shown To Reduce Adhd And Asd Symptoms In The Interim Results Of Its Second Efficacy Trial
Hong kong--(business wire)---- $rgc #adhd--regencell bioscience holdings limited (nasdaq: rgc) (“regencell”) today announced its interim results from its second efficacy trial. regencell conducted its second efficacy trial using standardized traditional chinese medicine (“tcm”) formulae. “our aim is to save and improve lives by making our standardized tcm formulae widely available to adhd and asd patients around the world. it is known that there is a significant economic impact and increased parental burden t
2022-09-12 09:15:00 - Press Release
Regencell Bioscience’s Standardized Formulae Are Shown To Reduce Adhd And Asd Symptoms In The Interim Results Of Its Second Efficacy Trial
Hong kong--(business wire)--regencell bioscience holdings limited (nasdaq: rgc) (“regencell”) today announced its interim results from its second efficacy trial. regencell conducted its second efficacy trial using standardized traditional chinese medicine (“tcm”) formulae. “our aim is to save and improve lives by making our standardized tcm formulae widely available to adhd and asd patients around the world. it is known that there is a significant economic impact and increased parental burden to families that care for children with adhd and asd. these positive data from the second efficacy trial bring us one step closer to improving the conditions and quality of life of patients and reducing the negative impact that adhd and asd have on patients and their families,” said yat-gai au, founder and ceo of regencell...
2022-05-18 08:05:00 - Press Release
Regencell Bioscience Announces Additional Earth Efficacy Trial Results Corroborating Effectiveness Of Its Investigational Liquid-formula Rgc-cov19tm In Eliminating Mild To Moderate Covid-19 Symptoms Within The 6-day Treatment Period
Hong kong--(business wire)---- $rgc #adhd--regencell bioscience holdings limited (nasdaq: rgc): results of earth efficacy trial earth efficacy trials period of trial 30 january 2022 – 31 march 2022 (earth-b trial) 1 october 2021 – 31 january 2022 (earth-a trial) 1 october 2021 – 31 march 2022 (earth-a and earth-b trials, combined) number of patients 51 37 88 complete symptoms elimination in 6 days (% of patients) 94.1 97.3 95.5 elimination of one or more symptoms after 1 full dose of rgc-cov19tm (% of patie
2022-05-16 08:56:00 - Press Release
Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases By Ceo
Hong kong--(business wire)---- $rgc #adhd--regencell bioscience holdings limited (nasdaq: rgc) (“regencell” or the “company”), an early-stage bioscience company focusing on the research, development and commercialization of traditional chinese medicine (“tcm”) for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people's immune system, announced that yat-gai au, the company's chairman and ceo, made purchases of ordinary shares in regencell (“ordinary shares
2022-05-16 07:00:00 - Press Release
Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases By Ceo
Hong kong--(business wire)--regencell bioscience holdings limited (nasdaq: rgc) (“regencell” or the “company”), an early-stage bioscience company focusing on the research, development and commercialization of traditional chinese medicine (“tcm”) for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people’s immune system, announced that yat-gai au, the company’s chairman and ceo, made purchases of ordinary shares in regencell (“ordinary shares”) totaling $5.03 million. based on his schedule 13d filings with the u.s. securities and exchange commission (the “sec”) between july 27, 2021 and may 16, 2022, mr. au used an aggregate of $5...
Latest News
2022-05-18 18:56:01 - Benzinga
Sector Rotation And 9 Stocks To Watch During A Recession
Is the United States heading toward a recession? This has been the looming question on the minds of Americans since inflation topped at 8.5% in March, matched with other indicators such as rising interest rates and the bond market's inverted yield curve.
2022-02-17 11:40:30 - Benzinga
Regencell Bioscience's COVID-19 Candidate Shows Encouraging Action On Mild To Moderate Symptoms
Regencell Bioscience Holdings Limited (NASDAQ: RGC) announced the results from the EARTH efficacy trial of its COVID-19 candidate. RGC-COV19 (Regencell Bioscience (RGCA-CV01) liquid formulation) is an oral TCM candidate.
2021-09-02 11:48:27 - Benzinga
Regencell Bioscience Stock Jumps On Formation Of COVID-19 Treatment Focused Joint Venture
Regencell Bioscience Holdings Ltd's (NASDAQ: RGC) subsidiary in Hong Kong has entered into a joint venture agreement with Honor Epic Enterprises Limited to offer COVID-19 related treatments. The joint venture will cater to patients in ASEAN countries, India, Japan, Australia, and New Zealand.
2021-08-25 06:41:16 - Pulse2
RGC Stock: Over 40% Pre-Market Details
The stock price of Regencell Bioscience Holdings Ltd (NASDAQ: RGC) increased by over 40% pre-market. This is why it happened.
2021-08-22 11:37:51 - Pulse2
Regencell Bioscience Shares Increased 204.13%: Why It Happened
The shares of Regencell Bioscience Holdings Ltd (NASDAQ: RGC) increased 204.13% in the previous trading session on August 20. This is why it happened.
2021-08-20 15:00:43 - PennyStocks
Is RGC Stock Rallying On Mistaken Identity?
Will RGC Stock Crash Or Go Higher After Today? The post Is RGC Stock Rallying On Mistaken Identity?
2021-08-20 08:00:00 - Business Wire
Regencell Bioscience Holdings Limited Announces Partial Exercise of Underwriter's Over-Allotment Option
HONG KONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ:RGC) ("Regencell" or the "Company"), an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine ("TCM") for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder ("ADHD") and Autism Spectrum Disorder ("ASD"), today announced that the underwriter of its initial public offering (the “Offering”) had
2021-07-16 14:05:00 - Barrons
7 Companies Begin Trading. Here's How They're Doing.
The group is diverse—a fintech, three biotechs, a real-estate investment manager, a bioscience company, and a pharmaceutical glassmaker.